Novo Drops NovoSeven Stroke Program Following Phase III Failure
This article was originally published in The Pink Sheet Daily
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
You may also be interested in...
Small molecule projects in development will be out-licensed, including the Phase I glucokinase activator NN9101.
Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.
Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.